Viva In Vitro Diagnostics — Seed (estimated) · €1.3M

Murcia-based biotech Viva in Vitro, an IMIB spin-off developing NLRP3 inflammasome-based diagnostics for sepsis stratification and personalised immunological medicine, closed its third round at €1.3 million led by regional venture capital company Murcia Emprende, with family offices and other private investors participating. The round takes the company past €3.2 million raised in total (about €2.6 million private plus roughly €600k in public grants).